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1. Introduction 
The modification of serine or threonine residues of nuclear and cytoplasmic proteins by the 
monosaccharide, β-D-Nacetylglucosamine was discovered in the early 1980s by Torres and 
Hart [1]. However, relative development in this field has remained sluggish for nearly two 
decades, mainly due to the lack of tools and techniques for the identification and 
quantification of O-GlcNAc modification in proteins. 
O-GlcNAc is a unique type of intracellular glycan attachment. Protein glycosylation 
traditionally refers to the covalent attachment of complex oligosaccharides to proteins in 
intraluminal compartments or cellular membranes, or in proteins that are destined for 
secretion. In contrast, O-GlcNAcylation is abundant in cytoplasmic and nuclear proteins, 
which are modified with a single β-N-acetylglucosamine monosaccharide moiety through 
an O-β-glycosydic attachment to serine and/or threonine side chains of the polypeptide 
backbone [2]. 
Because O-GlcNAc modification in protein occurs at serine/threonine residues, the potential 
for interplay between serine/threonine phosphorylation and O-GlcNAc modification has 
been realized very early on. However, unlike phosphorylation, which is regulated by 
hundreds of kinases and phosphatases, O-GlcNAc cycling has only two mediators: the 
enzymes O-GlcNAc transferase (OGT), and O-GlcNAc amidase (OGA) [2]. The addition and 
removal of O-GlcNAc is mediated by the concerted action of these two enzymes. Uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc) is the sugar donor for the O-GlcNAc 
modification, for glycophosphatidylinositol lipids synthesis, N-glycosylation, and other 
cellular processes. 
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2. Synthesis of UDP-GlcNAc from glucose via the hexosamine 
biosynthetic pathway 
The synthesis of UDP-GlcNAc from glucose occurs via the hexosamine biosynthetic 
pathway [3], as depicted in Figure 1. When glucose enters a cell, it becomes phosphorylated 
by hexokinase, and can be redirected from the main glycolytic/glycogen pathways to 
secondary pathways. About 2- 5% of intracellular glucose enters the hexosamine 
biosynthetic pathway (HBP); thus, the amount of protein GlcNAcylation is considered to be 
sensitive to the nutrient (i.e., glucose and/or glutamine). Glutamine/fructose 
aminotransferase (GFAT) commits glucose to this pathway, and represents the access to the 
HBP. This pathway links glycolytic metabolism with the amino acid metabolism via the 
requirement of glutamine to produce glucosamine-6-phosphate. The HBP pathway 
culminates with the formation of UDP-GlcNAc, the high-energy donor substrate for the O-
GlcNAc transferase. As can be observed in Figure 1, the biosynthesis of UDP-GlcNAc is 
affected and regulated by nearly every metabolic pathway in the cell, and because OGT-
catalyzed O-GlcNAcylation is sensitive to insulin, to nutrients, and to cellular stress, it has 
been proposed that O-GlcNAcylation serves primarily to modulate cellular signaling and 
transcription regulatory pathways in response to nutrients and stress [3- 6]. 
 
Figure 1. The synthesis of  Uridine diphospho--N-acetylglucosamine (UDP-GlcNAc) from glucose 
(Hexosamine biosynthetic pathway [HBP]) and the O-GlcNAcylation cycle. Glucose is metabolized 
through the HBP to form the high-energy intermediate UDP-GlcNAc, which serves as the three-sugar 
donor for O-linked N-acetylglucosaminyl transferase (OGT). This enzyme catalyzes the transfer of 
GlcNAc from UDP-GlcNAc to the OH of serine or threonine residues of a protein substrate through β-
glycosydic attachment. O-GlcNAcase hydrolyzes the glycosydic linkage to generate free GlcNAc and 
naked protein. The enzymes and the biosynthetic pathways involved in the process are depicted. 
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3. Enzymes that regulate O-GlcNAcylation cycle 
The enzymes that catalyze the addition and removal of O-GlcNAc have been cloned and 
characterized. Similar to phosphorylation, O-linked -N-acetylglucosamine (O-GlcNAc) 
modification of nuclear and cytosolic proteins is an abundant, dynamic, and inducible 
posttranslational modification. However, in mammals, only one enzyme attends to the 
transference of O-GlcNAc: the Uridine diphospho-N-acetylglucosamine polypeptide β-N-
acetylglucosaminyltransferase (OGT). This enzyme is regulated by binding partners as well 
as by posttranslational modification and alternative splicing. OGT interacts with several 
proteins that appear to target it to different locations inside the cell [4]. OGT is conserved 
from Caenorhabditis elegans to humans and it has been demonstrated that it is required for 
life because knock-out of the gene encoding OGT is lethal in embryonic mammalian stem 
cells [4]. The removal of O-GlcNAc is catalyzed by a neutral β-N-acetylglucosaminidase (O-
GlcNAcase). The main characteristics of the enzymes involved in the O-GlcNAcylation cycle 
are the following: 
3.1. OGT 
The gene encoding OGT has been cloned from several organisms and is well conserved. 
There is 99% identity between rat and human OGT, and 61% identity between rat and 
Caenorhabditis elegans OGT. In mammalian cells, OGT is encoded by a single copy X-linked 
gene, while in plants, there are two homologs: spy, and secret agent [7-9].  
OGT is expressed in all tissues studied, although it appears to be particularly rich in 
pancreas, brain, and thymus. OGT is a unique glycosyltransferase because it is a soluble 
protein rather than a type II membrane protein and has little or no homology to other 
glycosyltransferases. OGT contains two domains, an N-terminal Tetratricopeptide repeat 
(TPR) domain, and a C-terminal catalytic domain [7-9]. These domains are separated by a 
bipartite Nuclear localization sequence (NLS), thus, the enzyme is located predominantly 
within the nucleus. In mammalian cells, splicing of OGT mRNA leads to alternative 
transcripts, of which two are well characterized: mitochondrial OGT (mOGT), and 
nucleocytoplasmic OGT (ncOGT). mOGT has nine TPR repeats and an alternative N-
terminus, which contains a mitochondrial targeting sequence.  
ncOGT is the most widely studied of the known splice variants. It is a 1,037-amino-acid 
protein (110 kDa) and was thought to exist predominantly either as a homotrimer 
comprised of identical 110-kDa subunits or as a heterotrimer comprised of two identical 110-
kDa subunits coupled with a 78-kDa subunit. ncOGT was originally isolated from rat liver 
cytosol, has a pH optimum near 6 (active pH range, 6–7.5), and, unlike many 
glycosyltransferases, it is not dependent on divalent cations [7]. 
3.2. O-GlcNAcase 
O-GlcNAcase is a soluble, cytosolic β-N-acetylglucosaminidase expressed in all tissues 
examined and predominantly in brain. O-GlcNAcase is well conserved in mammals, with 
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97.8% identity between the human and the mouse gene and with 29% identity between the 
human and the C. elegans gene [10]. In contrast to lysosomal hexosaminidases (A and B), O-
GlcNAcase is specific for β-N-acetylglucosamine, is not inhibited by N-acetylgalactosamine, 
and has a neutral optimum pH of 5.5–7 (lysosomal hexosaminidases have pH ∼3.5–5.5). O-
GlcNAcase co-purifies with a complex of proteins, is probably regulated by its interactions 
with other proteins, and is phosphorylated, suggesting an additional mechanism for its 
regulation [10]. O-GlcNAcase is efficiently inhibited by O-(2-acetamido-2-deoxy-D-
glucopyranosylidene) amino-N-phenylcarbamate (PUGNAc; Ki 54 nm). It is a 917-amino-
acid protein, with at least two functional domains: an N-terminal hexosaminidase domain, 
and a C-terminal histone acetyltransferase (HAT) domain [11]. It has been shown that the C-
terminal domain of O-GlcNAcase acetylates both free-core histones and nucleosomal 
histone proteins. Consistent with these data, OGT is known to associate with histone 
deacetylase complexes and to promote transcriptional silencing and dynamic modification 
of transcriptional complexes by O-GlcNAc and histone [11]. 
4. O-GlcNAc-phosphorylation interplay  
Glycomic analyses have shown that O-GlcNAcylation has extensive cross-talk with 
phosphorylation, where it serves as a nutrient/stress sensor to modulate signaling, 
transcription, and cytoskeletal functions. Nearly all O-GlcNAc-modified proteins are also 
phosphorylated, supporting the notion that interplay exists between the two modifications 
[3]. Indeed, it has been reported that O-GlcNAcylation and phosphorylation both occur in 
serine and threonine residues in many instances, and that the two modifications can 
compete for occupancy at the same site or at adjacent residues [12]. Therefore, it has been 
proposed that a Yin-Yang relationship does exist at the global level as well as at specific sites 
in several proteins. YinOYang prediction residues refer to S/T residues that can be either 
phosphorylated or modified by O-GlcNAc (http://www.cbs.dtu.dk/services/YinOYang/).  A 
recently developed Website contains the most up-to-date list of published O-GlcNAc 
modification sites and an algorithm to predict whether a site might be O-GlcNAcylated 
(http://cbsb.lombardi.georgetown.edu/hulab/OGAP.html) [3]. However, subsequent studies 
have identified increasing numbers of O-GlcNAc modification sites that are adjacent or even 
distal to phosphorylation sites. In addition, pharmacologically inhibiting dephosphorylation 
does not decrease O-GlcNAcylation in all proteins, and inhibition of OGA or overexpression 
of OGT can produce increases in phosphorylation [13]. Thus, these data suggest a complex 
interplay between the two modifications. Therefore, although regulatory roles of O-GlcNAc 
interplay with phosphorylation occur, the binary Yin-Yang model is extremely simplistic 
and it is noteworthy that different types of interplay between these two posttranslational 
modifications can take place [12, 13]. 
Our understanding of the regulatory mechanisms involved in O-GlcNAc modification and 
its interplay with serine/threonine phosphorylation in proteins remains elusive. This is 
probably due to the fact that O-GlcNAcylation remained undetected until the early 1980s by 
commonly used analytical protein methods, including gel electrophoresis and the majority 
of forms of High-pressure liquid chromatography (HPLC) [3]. For example, addition of the 
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sugar does not generally affect migration of a polypeptide in gel electrophoresis, or upon 
isoelectric focusing, or even in high-resolution, two-dimensional gels. In addition, the sugar 
modification is rapidly hydrolyzed by cellular hexosaminidases upon cellular damage or 
during protein isolation if countermeasures are not employed [3]. A major breakthrough in 
the detection and site mapping of O-GlcNAc occurred first with the development of Fourier 
transform mass spectrometers capable of Electron capture dissociation (ECD), and 
subsequently with the development of ion-trap mass spectrometers, which could perform 
Electron transfer dissociation-Mass spectrometry (ETD-MS). These recent successes in O-
GlcNAc modification-site mapping in proteins have revealed two important clues: first, 
nearly all O-GlcNAc modified proteins are known phospho-proteins, and second, the 
prevalence of tyrosine phosphorylation among O-GlcNAc- modified proteins is 
exceptionally higher (~68%) than its normal occurrence (~2%) alone [2]. In this respect, 
Mishra S et al [14] recently reported that tyrosine phosphorylation interacts with O-GlcNAc 
modification, a phenomenon not previously known [14]. Subsequently, two additional 
articles were published showing that O-GlcNAc modification of Insulin receptor substrate 1 
(IRS1) occurs in close proximity of tyrosine phosphorylation sites and affects the tyrosine 
phosphorylation-dependent function of IRS1 [15,16]. 
The extensive cross-talk between O-GlcNAcylation and phosphorylation represents a new 
paradigm for cellular signaling. Accurate delineation of the complex cross-talk between O-
GlcNAcylation and phosphorylation could elucidate the global complex regulatory 
mechanism vital for cellular functions, such as regulation of cell cycle and cell growth, 
proliferation, and apoptosis. 
5. O-GlcNAcylation in cell signaling and cellular stress 
A generalization with respect to the roles of O-GlcNAcylation in cellular signaling has 
emerged during the past two decades. The primary function of O-GlcNAcylation appears to 
be the modulation of cellular processes in response to nutrients and to cellular stress [3, 17]. 
Cells dynamically induce O-GlcNAc protein modification in response to numerous forms of 
cellular stress, and this appears to be a protective response of cells. For example, blocking 
the hexosamine biosynthetic pathway ablates glucose-mediated cellular protection [18]. 
Raising O-GlcNAc levels by either inhibition of O-GlcNAcase or overexpression of OGT 
rendered cells more tolerant to several forms of stress, such as exposition to ultraviolet (UV) 
irradiation, ethanol, and sodium arsenite [18].  
Many transcription factors are modified by O-GlcNAcylation in response to physiological 
stimuli, cell cycle stage, and developmental stage, and this modification can modulate their 
function in different ways [19]. O-linked GlcNAc moieties on transcription factors may be 
recognized by several components of the transcriptional machinery, serve as a nuclear 
localization signal, antagonize the action of protein kinases by masking potential serine and 
threonine sites for phosphorylation, modulate DNA binding activity or half-life, and 
increase the stability of transcription factors in the cell [19]. Although quantitatively the 
majority of O-GlcNAc occurs in chromatin proteins, many cytosolic enzymes, including 
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kinases, glycolytic enzymes, the majority of cytoskeleton regulatory proteins, and the 
cytoskeleton proteins themselves are also modified [3]. In most cells, OGT is found mainly 
within the nucleus, and O-GlcNAcase is found mainly within the cytosol. In the following 
section, we will describe how O-GlcNAcylation affects cellular signaling, using as examples 
the following four proteins involved in carcinogenesis: 
5.1. O-GlcNAc modification of protein kinase C (PKC) 
PKC comprises a family of 10 lipid-dependent serine/threonine kinases that play key roles in 
proliferation and cell cycle progression, differentiation, tumorigenesis, apoptosis, 
cytoskeletal remodeling, ion-channel modulation, and secretion. Activation of PKC 
isozymes is dependent on tyrosine-kinase receptors and G-protein-coupled receptors. Based 
on differences in sequence homology and in biochemical properties, PKC isozymes have 
been classified into three subfamilies: the conventional PKC isozymes (cPKC) α, βI, βII, and 
γ, which are dependent on diacylglycerol (DAG) and Ca2+ for their activity and which 
respond to phorbol esters; the novel PKC (nPKC) δ, ε, η, and θ, which are insensitive to Ca2+ 
but DAG-dependent, and the atypical PKC (aPKC) ι/λ and ζ, which neither require Ca2+ nor 
respond to DAG or phorbol esters [20]. 
It has been reported that increased flux through hexosamine biosynthetic pathway affects 
the activity and translocation of certain PKC isoforms [21]. We reported for the first time 
that conventional, novel, and atypical PKC isozymes are all posttranslationally modified by 
O-GlcNAc [20]. Activation of PKC is generally correlated with its serine-theonine 
phosphorylation and translocation to cell membranes, but it has been also shown that other 
posttranslational modifications (PTM), such as tyrosine phosphorylation or tyrosine 
nitration, may modulate PKC activity [22, 23] 
We have investigated the posttranslational modifications induced on PKC isozymes as 
result of their activation upon exposure of cells to a direct PKC activator (the phorbol ester 
Tetradecanoyl phorbol acetate [TPA]), or to an extracellular ligand known to activate PKC-
dependent pathways [20]. Using freshly isolated rat hepatocytes, we studied the effect of 
epinephrine on PKC isoforms via activation of α1-adrenergic receptors in comparison with 
acute TPA treatment. The cells were incubated for 5 min in the absence (vehicle) or presence 
of 1 μM TPA or 10 μM epinephrine plus 10 μM propranolol (β-adrenergic antagonist). PKC 
isozymes were immunoprecipitated from cell extracts, and the posttranslational 
modifications produced on them were analyzed by Western blotting utilizing antibodies 
that recognizes O-linked GlcNAc in proteins (Affinity Bioreagents, Inc). 
We found that posttranslational modifications other than Ser/Thr phosphorylation, such as 
tyrosine nitration and tyrosine phosphorylation, are commonly present in all PKC isozymes 
and that they change rapidly and dynamically in response to extracellular stimuli [20]. Our 
data demonstrated for the first time that all PKC isozymes are also dynamically modified by 
O-linked β-N-acetylglucosamine (O-GlcNAc); the presence of this modification was 
confirmed in part by Fourier transformation-Ion cyclotron resonance (FT-ICR) mass 
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spectrometry analysis, and interestingly, the O-GlcNAc modified Ser or Thr were mapped at 
similar positions in several PKC isozymes.  
General analysis of the collected data showed several interesting things [20]. First, it was 
noteworthy that O-GlcNAc modification appeared at similar positions in all PKC isoforms, 
such as the middle part of the molecule. Second, despite the percentage of sequence identity 
varied between PKC isoforms, the O-GlcNAc-modification was found in different peptides 
with similar sequences shared by several isozymes, and third, in many instances, the 
probably modified residue found agreed with the predicted O-GlcNAc potential sites 
(http://www. cbs.dtu.dk/services/YinOYang/), with YinOYang predictions (S/T residues that 
can be either phosphorylated or modified by O-GlcNAc), and in the case of PKCε, matched 
exactly with T710 located at ‘turn motif’, which is known to be an autophosphorylation 
‘priming site’. In other instances, the modified residue found did not exactly match the 
predicted ones, but were mapped near the phosphorylation ‘priming sites’: T517 in PKC 
epsilon, located immediately prior to the beginning of ‘activation loop’, T689 and S690, 
present at the end of the ‘hydrophobic motif’ of PKCγ, or S670, present at ‘turn motif’ in 
PKCθ, immediately prior to the S676 ‘priming site’. Therefore, these findings suggest that O-
GlcNAcylation and phosphorylation may modulate each other. 
The biochemical meaning of these posttranslational modifications for PKC alpha and PKCδ 
activity was investigated [20]. The results obtained suggested that while Ser/Thr 
phosphorylation at C terminus and tyrosine phosphorylation status appear to regulate the 
activation states of both PKCα and PKCδ isozymes, only PKCα activity appears to be 
regulated as well, in this case, in a negative manner, by tyrosine nitration and O-GlcNAc 
posttranslational modifications. Thus, our data indicated that phosphorylation status, both 
in Ser/Thr and in Tyr residues, may regulate the activity of all PKC isozymes, but the 
biochemical consequences of tyrosine nitration and O-GlcNAc modifications may be 
different for each PKC isozyme.  
5.2. O-GlcNAc modification of c-Myc 
c-Myc (v-myc myelocytomatosis viral oncogene homolog), a helix-loop-helix leucine zipper 
transcription factor, contributes to the development of several malignancies. In a normal 
resting cell, c-Myc levels are very low. However, upon mitogenic stimulation, c-myc 
expression levels are highly increased, as well as upon canonical Wnt signaling stimulation.  
C-myc heterodimerizes with Max to regulate transcription of proliferation and cell 
differentiation genes [24]. Cell proliferation requires the coordinated activity of cytosolic 
and mitochondrial metabolic pathways to provide ATP and building blocks for DNA, RNA, 
and protein synthesis. Many metabolic pathway genes are targets of the c-myc oncogene 
and cell-cycle regulator. Morris F et al [25] demonstrated that Myc expression also increased 
global O-linked N-acetylglucosamine protein modification, and inhibition of hexosamine 
biosynthesis selectively reduced growth of Myc-expressing cells, suggesting its importance 
in Myc-induced proliferation. 
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c-Myc can be phosphorylated by casein kinase II [26] and by Mitogen-activated protein 
kinase (MAP kinase) [24]. It also has been reported that can be modified by O-GlcNAc [28, 
29]. Phosphorylation at Thr-58 and/or Ser-62 in the N-terminal transcription 
activation/malignant transformation domain (TAD) of c-Myc may modulate transactivation 
and co-transformation by c-Myc [29].  
The O-GlcNAc modification of c-Myc has been identified both in mammalian (rabbit 
reticulocyte lysate and Chinese hamster ovary [CHO]) cell line and in insect cell systems 
[19]. This modification of c-Myc was shown by three different methods as follows: (i) 
demonstration of lectin- binding to in vitro translated protein using a protein-protein 
interaction mobility-shift assay; (ii) glycosidase or glycosyltransferase treatment of in vitro 
translated protein analyzed by lectin-affinity chromatography, and (iii) direct 
characterization of the sugar moieties on purified recombinant protein overexpressed in 
either insect cells or CHO cells [29]. O-GlcNAc-modified sites within c-Myc were originally 
found to be located near the transcriptional activation domain [28]. A later study identified 
Thr-58, an in vivo phosphorylation site in the transactivation domain, as the major site of O-
GlcNAc modification [29]. This suggests a mutually exclusive modification of c-Myc by 
either phosphorylation or O-GlcNAc modification. The transactivation domain of c-Myc 
associates with the tumor suppressor Retinoblastoma protein Rb and the Rb-related protein 
p107 in vitro [19, 30]. Thus, the presence of O-GlcNAc modification on c-Myc may result in 
altered interaction with Rb and Rb-related protein p107, thereby interfering with 
transactivation by c-Myc. Interestingly, Thr-58 is located within a mutational hot spot in 
lymphomas, suggesting that this region is associated with increased tumorigenicity [19]. 
5.3. O-GlcNAc modification of β-catenin 
The Wnt pathway plays an important role in development and in regulation of adult stem-
cell systems. Deregulation of Wnt signaling causes developmental defects and cancer. 
Canonical Wnt signaling operates through regulating the phosphorylation and degradation 
of the transcription co-activator -catenin [31]. Without stimulation by Wnt, -catenin is 
assembled into the so-called “destruction complex” in which Adenomatous polyposis coli 
(APC) plays a central role, and includes Axin, Glycogen synthase kinase 3 (GSK3), and 
Casein kinase 1 (CK1). This complex directs a series of phosphorylation events on -catenin 
that targets it for ubiquitination and subsequent proteolysis via the proteasome. Stimulation 
by Wnt leads to inhibition of -catenin breakdown, allowing -catenin to accumulate, enter 
the nucleus, and activate a Wnt target gene program [31, 32]. 
The phosphorylation of β-catenin is key in the regulation of its intracellular levels, hence in 
its transcriptional activity. Nuclear -catenin is the hallmark of activated canonical Wnt 
signaling. Thus, nuclear import/export of -catenin represents a crucial step in regulating 
signaling competent -catenin levels and serves as an attractive target for pharmacological 
interventions in cancer and other diseases associated with altered Wnt signaling. However, 
the mechanisms that regulate the nuclear localization of -catenin remain unclear. -catenin 
contains no recognizable NLS; thus, it has been proposed that it is imported by a piggy-back 
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mechanism. However, it has been demonstrated that -catenin nuclear import can occur in 
the absence of transport factors, such as importins or the Ran GTPase [33]. Moreover, -
catenin was found to compete with importin- for docking to components of the nuclear 
pore complex. Indeed, the central arm repeats are required for -catenin import, and these 
are structurally related with the importin- HEAT (Huntington, Elongation factor 3, 
PR65/A, TOR) repeats that bind the nuclear pore complex [34]. With respect to the -catenin 
nuclear export, although the precise mechanism is not completely understood, several 
distinct -catenin nuclear export pathways have been reported to date. 
Sayet et al [35] demonstrated that O-GlcNAcylation of β-catenin negatively regulates its 
levels in the nucleus. TCF reporter plasmid (TOPflash) reporter assays and mRNA 
expression of β-catenin's target genes indicated that O-GlcNAcylation of β-catenin results in 
a decrease in its transcriptional activity. The authors showed also that this novel 
modification of β-catenin regulates its nuclear localization and transcriptional function. 
Their results indicated that O-GlcNAcylation of β-catenin is inversely related to its nuclear 
localization and transcriptional function. This finding highlights O-GlcNAcylation as a new 
level of regulation of β-catenin transcriptional function.  
5.4. O-GlcNAc modification of p53 
The tumor suppressor protein p53 is a cell cycle regulator, and mutations in p53 cause 
cancer. This protein is considered the major ‘gatekeeper’ of genomic stability. Under 
conditions of cellular stress, environmental damage or genetic catastrophe, p53 expression 
and stability increase, followed by the induction of genes that promote cell-cycle arrest, 
apoptosis, and autophagy [13].  
Owing to the pivotal role of p53 in maintaining genomic integrity, p53 is tightly regulated 
by proteolytic degradation. Normally, p53 levels are low due to continuous degradation by 
ubiquitin-dependent proteolysis. In unstressed cells, p53 interacts with Mdm2, which acts as 
an ubiquitin ligase, leading to degradation of p53 by the proteasome [36, 37]. The stability of 
p53 is also affected by phosphorylation. The amino-terminal domain of the tumor 
suppressor contains the transactivation domain and several known phosphorylation sites. 
Phosphorylation at Ser18 and Ser23 promotes p53 stability and tumor suppression, and 
phosphorylation of p53 at Thr155 (which resides in the DNA-binding domain) promotes p53 
degradation by the COP9 signalosome [38]. 
The mechanism by which O-GlcNAc modification enhances p53 stability has been recently 
established by the identification of the O-GlcNAc residue within p53 employing mass 
spectrometry (MS). Activation of p53 by stress involves the O-GlcNAc modification of Ser-
149, and modification of this site interferes with phosphorylation at Thr-155 by means of the 
COP9-associated kinases. Lowering phosphorylation at Thr-155 weakens the interaction of 
p53 with Mdm2 and decreases p53 ubiquitination/proteolysis, resulting in higher stability of 
the p53 protein [39]. However, mutating Ser-149 to Ala does not significantly decrease O-
GlcNAc modification of p53 [39], suggesting that in addition to Ser-149, there are other 
residues within p53 that become O-GlcNAc-modified. 
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6. O-GlcNAcylation and cancer 
Altered O-linked GlcNAc modification has been linked with several human diseases, 
including cardiovascular disease, neurodegenerative disorders, diabetes mellitus, and 
cancer [13]. Given the extensive cross-talk between O-GlcNAcylation and phosphorylation 
and the known roles of phosphorylation in mechanisms underlying cancer, it is not 
surprising that O-GlcNAcylation is also involved in the etiology of cancer. 
The unique metabolism of tumors was described many years ago by Otto Warburg, who 
identified tumor cells with increased glycolysis and decreased mitochondrial activity [40]. 
Warburg found that normal tissues used mitochondrial oxidation to account for 90% of ATP 
production, with glycolysis accounting for 10%. However, tumors used less of the highly 
efficient oxidative phosphorylation, producing < 50% of ATP from oxidation and >50% from 
glycolysis. This shift was thought to occur even though there was sufficient oxygen to 
support mitochondrial function and is called ‘‘aerobic glycolysis’’ [40]. 
Aerobic glycolysis is just one component of the metabolic transformation. In order to engage 
in replicative division, a cell must duplicate its genome, proteins and lipids and assemble 
the components into daughter cells; in short, it must become a factory for macromolecular 
biosynthesis. Thus, enhanced biosynthetic capacity is a key feature of the metabolic 
transformation of tumor cells. Synthesis of nucleotides and fatty acids and consumption of 
glucose and glutamine are widespread among tumors and tumor cell lines. It appears likely 
that these activities, particularly the use of glutamine as a source of both reductive power 
and anaplerosis, are general characteristics of tumor cell growth and proliferation [41]. 
Glutamine contributes essentially to every core metabolic task of proliferating tumor cells: it 
participates in bioenergetics, supports cell defenses against oxidative stress, and 
complements glucose metabolism in the production of macromolecules [41]. Interest in 
glutamine metabolism has been further heightened by recent findings that c-myc  controls 
glutamine uptake and degradation, and that glutamine itself exerts influence over a number 
of signaling pathways that contribute to tumor growth [13, 41]. Because HBP flux and UDP-
GlcNAc availability are directly affected by many different nutrients, such as glucose, fatty 
acids, and amino acids, it is possible that in cancer cells, the HBP, together with O-GlcNAc 
modification, serves as a glucose/nutrient sensor that links metabolism to the activation of 
many oncogenic signaling pathways within the cell. 
Western blot methods showed decreased O-GlcNAc levels in some tumor samples 
compared with controls. However, other studies suggested that O-GlcNAc levels increase in 
some cancers. There are potential sources of confusion from these studies. Crucial 
tumorigenic roles of specific O-GlcNAcylated proteins might be masked on analyzing only 
global cellular O-GlcNAcylation. In addition, cellular levels of O-GlcNAc, OGT, and OGA 
have a tight relationship with multiple cellular activities. Despite conflicting data in primary 
tumor samples, increased O-GlcNAcylation does appear to be a general characteristic of 
cancer cells. Histological sections from breast, lung, and colon tumors demonstrated 
increased O-GlcNAcylation compared with matched adjacent tissue [42]. In the case of the 
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lung and colon tissue, both OGT and OGA expression appeared to increase. Similarly, in 
patients with chronic lymphocytic leukemia, the O-GlcNAcylation of proteins was increased 
when compared with normal lymphocytes [43]. Furthermore, breast cancer cells in which 
OGT was knocked down and that were transplanted into nude mice formed fewer tumors 
compared with controls [13]. 
Chemotherapeutics targeting OGT or OGA inhibition could potentially alter tumor function 
or could render tumors more susceptible to other chemotherapeutic agents; however, which 
adverse affects OGT or OGA inhibition might have on normal cells is unknown. 
7. Conclusions 
Many cytoplasmic and nuclear proteins are dynamically modified by O-linked β-N-
acetylglucosamine (O-GlcNAc). However, the precise function that it carries out on each 
protein remains unknown. Interestingly, O-GlcNAc shares many common traits with O-
phosphate. They are both dynamic modifications processed by specific enzymes that modify 
serine/threonine residues and that rapidly respond to extracellular stimuli. Posttranslational 
modifications are essential devices to generate the tremendous diversity, complexity, and 
heterogeneity of gene products. Determination of the in vivo roles that they play is one of 
the main challenges in proteomics and signal transduction research. 
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